CN110840950A - Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury - Google Patents
Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury Download PDFInfo
- Publication number
- CN110840950A CN110840950A CN201911069426.1A CN201911069426A CN110840950A CN 110840950 A CN110840950 A CN 110840950A CN 201911069426 A CN201911069426 A CN 201911069426A CN 110840950 A CN110840950 A CN 110840950A
- Authority
- CN
- China
- Prior art keywords
- russian tea
- extract
- russian
- tea
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241001122767 Theaceae Species 0.000 title claims abstract description 105
- 239000000284 extract Substances 0.000 title claims abstract description 85
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 13
- 231100000753 hepatic injury Toxicity 0.000 title claims abstract description 12
- 208000022309 Alcoholic Liver disease Diseases 0.000 title claims abstract description 10
- 230000001476 alcoholic effect Effects 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 229940079593 drug Drugs 0.000 title abstract description 10
- 210000004185 liver Anatomy 0.000 claims abstract description 29
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 239000000287 crude extract Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 9
- 238000002137 ultrasound extraction Methods 0.000 claims description 9
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 208000019423 liver disease Diseases 0.000 abstract description 8
- 235000009200 high fat diet Nutrition 0.000 abstract description 7
- 210000005229 liver cell Anatomy 0.000 abstract description 5
- 238000009825 accumulation Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 238000000605 extraction Methods 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 23
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 10
- 230000002055 immunohistochemical effect Effects 0.000 description 8
- 239000006286 aqueous extract Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating nonalcoholic liver diseases and/or nonalcoholic liver injury. The Russian tea and/or the Russian tea extract has a remarkable prevention and treatment effect on the non-alcoholic liver disease. Through application, the Russian tea extract can effectively inhibit the increase of the liver coefficient, so that the production of non-alcoholic fatty liver is inhibited; the Russian tea can effectively inhibit the accumulation of fat in liver cells caused by long-term high-fat diet. The Russian tea and/or the Russian tea extract used for preparing the medicine for preventing and treating the non-alcoholic liver disease have the following advantages: the Russian tea is widely distributed in China and is low in price; the Russian tea is an edible natural plant material, and has high safety; the process flow of the extraction and preparation of the Russian tea is convenient and simple.
Description
Technical Field
The invention relates to the technical field of nonalcoholic liver disease treatment, in particular to application of Russian tea and/or Russian tea extract in preparation of a medicine for preventing and treating nonalcoholic liver disease and/or nonalcoholic liver injury.
Background
Non-alcoholic fatty liver disease (NAFLD) refers to a clinical pathological syndrome characterized mainly by excessive fat deposition in liver cells due to alcohol and other definite liver damage factors, and acquired metabolic stress liver injury closely related to insulin resistance and genetic susceptibility. Including Simple Fatty Liver (SFL), non-alcoholic steatohepatitis (NASH) and its associated cirrhosis. With the prevalence trend of obesity and its associated metabolic syndrome globalization.
NAFLD can directly cause diseases such as compensatory liver cirrhosis, liver cancer and the like, can also affect the progress of other chronic liver diseases, and is involved in the onset of type 2 diabetes and atherosclerosis. Malignant tumors associated with metabolic syndrome, arteriosclerotic cardiovascular and cerebrovascular diseases, and liver cirrhosis are important factors affecting the quality of life and life expectancy of patients with NAFLD. However, there is currently no clinical therapeutic drug specifically targeted at NAFLD, making NAFLD a great challenge in the contemporary medical field.
Disclosure of Invention
The invention aims to provide application of Russian tea and/or Russian tea extracts in preparation of medicines for preventing and treating nonalcoholic liver diseases and/or nonalcoholic liver injuries.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating nonalcoholic liver diseases.
Preferably, the non-alcoholic liver disease comprises non-alcoholic fatty liver disease and/or non-alcoholic fatty liver complications.
The invention also provides application of the Russian tea and/or the Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver injury.
The invention also provides application of the Russian tea and/or the Russian tea extract in preparing food, health-care products or medicines for protecting the liver and/or inhibiting fat particle deposition in the liver.
Preferably, the medicine also comprises pharmaceutically acceptable auxiliary materials.
Preferably, the dosage form of the medicine comprises powder, granules, pills, tablets, capsules, paste or decoction.
Preferably, the russian tea extract comprises a russian tea alcohol extract and/or a russian tea water extract.
Preferably, the russian tea alcohol extract is prepared by the following method: mixing Russian tea with an ethanol water solution, performing ultrasonic extraction to obtain a crude extract, centrifuging the crude extract, and collecting the supernatant to obtain Russian tea ethanol extract; the volume percentage of the ethanol in the ethanol water solution is 75-85%.
Preferably, the temperature of ultrasonic extraction is 20-30 ℃, the time is 25-35 min, and the ultrasonic power is 30-40 Kw.
Preferably, the russian tea water extract is prepared by the following method: mixing the Russian tea with water, boiling for 0.8-1.5 h at 95-105 ℃ to obtain a crude extract, centrifuging the crude extract, and collecting the supernatant to obtain the Russian tea water extract.
The invention has the beneficial effects that: the invention provides application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating nonalcoholic liver diseases. The Russian tea and/or the Russian tea extract has a remarkable prevention and treatment effect on the non-alcoholic liver disease. Through application, the Russian tea extract can effectively inhibit the increase of the liver coefficient, so that the production of non-alcoholic fatty liver is inhibited; the Russian tea can effectively inhibit the accumulation of fat in liver cells caused by long-term high-fat diet. The Russian tea and/or the Russian tea extract used for preparing the medicine for preventing and treating the non-alcoholic liver disease have the following advantages: the Russian tea is widely distributed in China and is low in price; the Russian tea is an edible natural plant material, and has high safety; the process flow of the extraction and preparation of the Russian tea is convenient and simple.
Drawings
FIG. 1 is a pathological section of rat liver in example 2, in which FIG. 1-A is a pathological section of rat liver in control group; FIG. 1-B is a pathological section of rat liver in model group; FIG. 1-C is a pathological section of liver of rat in low concentration group of alcohol extract; FIG. 1-D is a pathological section of liver of rat in high concentration group of alcohol extract; FIG. 1-E is a pathological section of liver of rats in a group with low concentration of water extract; FIG. 1-F is a pathological section of liver of rat in high-concentration water extract group;
FIG. 2 is a section view of immunohistochemical FAS in example 2, wherein FIG. 2-A is a section view of immunohistochemical FAS of a control group; FIG. 2-B is a section view of a model set immunohistochemical FAS; FIG. 2-C is a sectional view of an immunohistochemical FAS of the alcohol extract low concentration group; FIG. 2-D is a sectional view of an ethanol extract high concentration immunohistochemical FAS; FIG. 2-E are sectional views of immunohistochemical FAS of the water extract low concentration group; FIG. 2-F is a slice of an aqueous extract immunohistochemical FAS in a high concentration group.
Detailed Description
The invention provides an application of Russian tea and/or Russian tea extract in preparing a medicine for preventing and treating nonalcoholic liver diseases; the non-alcoholic liver disease preferably comprises non-alcoholic fatty liver disease and/or non-alcoholic fatty liver complications.
The invention also provides application of the Russian tea and/or the Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver injury.
The invention also provides application of the Russian tea and/or the Russian tea extract in preparing food, health-care products or medicines for protecting the liver and/or inhibiting fat particle deposition in the liver.
In the present invention, the pharmaceutical product preferably further comprises pharmaceutically acceptable excipients.
In the invention, the dosage form of the medicine preferably comprises powder, granules, pills, tablets, capsules, paste or decoction.
In the invention, the Russian tea extract preferably comprises a Russian tea alcohol extract and/or a Russian tea water extract.
In the invention, the Russian tea alcohol extract is prepared by adopting the following method: mixing Russian tea with an ethanol water solution, performing ultrasonic extraction to obtain a crude extract, centrifuging the crude extract, and collecting the supernatant to obtain Russian tea ethanol extract; the volume percentage content of the ethanol in the ethanol water solution is 75-85%, and the preferred volume percentage content is 80%.
In the invention, the Russian tea is collected from Sichuan province, and a sample is stored in the research institute of food safety in Yunnan province; the volume ratio of the Russian tea to the ethanol water solution is preferably 1: 9-11, and more preferably 1: 10; the ultrasonic extraction temperature is preferably 20-30 ℃, and more preferably 25 ℃; the number of times of ultrasonic extraction is preferably 3, and the time of each ultrasonic extraction is preferably 25-35 min, and more preferably 30 min; the power of ultrasonic extraction is preferably 30-40 Kw, and more preferably 35 Kw; the rotation speed of the centrifugation is preferably 3000-5000 rpm, and more preferably 4000 rpm; the centrifugation time is preferably 5-15 min, and more preferably 10 mim; after the Russian tea alcohol extract is obtained, the Russian tea alcohol extract is preferably subjected to freeze drying. Under the optimized condition, the pure Russian tea extract has the highest content of polyphenol brass, the best effects of resisting oxidation and inhibiting apoptosis and the obvious liver protection effect.
In the invention, the Russian tea aqueous extract is preferably prepared by the following method: mixing Russian tea with water, boiling for 0.8-1.5 h at 95-105 ℃ to obtain a crude extract, centrifuging the crude extract, and collecting the supernatant to obtain a Russian tea water extract; the volume ratio of the Russian tea to the water is preferably 1: 14-16, and more preferably 1: 15; the cooking temperature is preferably 100 ℃; the cooking time is preferably 1-1.2 h; the rotation speed of the centrifugation is preferably 3000-5000 rpm, and more preferably 4000 rpm; the time of the centrifugation is preferably 10 min; after the Russian tea water extract is obtained, the method preferably further comprises the steps of carrying out suction filtration and freeze drying on the Russian tea water extract. Under the optimized condition, the content of polysaccharide in the Russian tea water extract is highest, and the reported effect is obvious.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1 preparation of Russian tea extract
1. Preparing the Russian tea alcohol extract: ultrasonic extracting with 80% ethanol solution at 25 deg.C under working voltage of 220V/50KHZ V and power of 35Kw for 30min, extracting the residue for three times, centrifuging at 4000r/min for 10min, collecting supernatant, mixing the supernatants, and lyophilizing.
2. Preparing an aqueous extract of Russian tea: the water extract mainly simulates the characteristic of decoction in pharmacopoeia, and is boiled in boiling water for 1h, and the material-liquid volume ratio is 1: 15. Centrifuging at 4000r/min for 10min after boiling, vacuum filtering the supernatant, and lyophilizing at (-55 deg.C, vacuum degree of 200, 48 h).
Example 2
A model of NAFLD is established by feeding high fat feed, and the prevention and treatment effect of ethanol and water extract of Russian tea on NAFLD is observed by animal model experiment.
1. Experimental Material
1.1 animal, feed and reagents
SD male rats, Liaoning Biotechnology GmbH. High fat diet, available from Toyobo biology Ltd. The kit is built by Nanjing Biotechnology GmbH and Biyuntian Biotechnology GmbH.
1.2 instruments
Full-automatic biochemical analyzer, Shenzhen Redu Life sciences GmbH.
2. Method and results
2.1 Molding
The male rats are SPF SD rats aged 4-8 weeks, and the weight deviation is about 5% when the weight is about 200 g. The experimental animals were from Schleksideda, Inc. in Hunan, and the rat was SCXK (Hunan) 2016-. Specifically, 48 mice were divided into 6 groups (8 mice per cage), and the aqueous and alcoholic extracts were used in two groups. The numbering is as follows:
group K: a control Group (distilled water for gastric gavage, K), a Group M model Group (distilled water for gastric gavage, M), a Group AL alcohol extract low-dose Group of 200mg/kg (russian tea alcohol extract prepared in example 1, AL), a Group AH alcohol extract high-dose Group of 600mg/kg (russian tea alcohol extract prepared in example 1, AH), a Group WL water extract low-dose Group of 200mg/kg (russian tea water extract prepared in example 1, WL), and a Group WH water extract high-dose Group of 600mg/kg (russian tea water extract prepared in example 1, WH). All animals were fasted for 12h prior to the first dose, and the body weight of each mouse was recorded prior to dosing (water deprivation). Rats were housed in a standard rat housing environment (after purchase, rats were acclimated to this environment for seven days). The molding mode is as follows: the corresponding dose of the two extracts or distilled water is infused with the intragastric volume of 5mL/kg at 9 am every day. After gavage, each group was free to eat high fat diet. After 90 days of feeding, all rats are fasted for 12h, anesthetized with 10% chloral hydrate, weighed, blood is taken to prepare serum to be tested, and then biochemical analysis of the serum is carried out; weighing the liver, then taking the left lobe of the liver, immersing the liver in a 10% formalin solution, and carrying out H & E staining and immunohistochemistry.
2.2 results
2.2.1 Effect of Russian tea extract on body weight and liver index of non-alcoholic fatty liver rats.
TABLE 1 Effect of Russian tea extract on liver index of non-alcoholic fatty liver rats
Note: superscript with significant differences compared to control#(p<0.05); the superscript of the significant difference compared to the model group is: (p)<0.05)。
As can be seen from table 1, the liver index of the model group induced by high fat diet was significantly increased (p <0.05) compared to the control group; the liver index of mice given the samples of the alcoholic russian tea extract and the aqueous russian tea extract was significantly reduced compared to the model group, wherein the liver index of the high concentration group (AH) of the alcoholic russian tea extract was most significantly reduced and the effect was the best. Therefore, the Russian tea can effectively inhibit the increase of the liver coefficient, so that the production of the non-alcoholic fatty liver is inhibited.
2.2.2 Effect of Russian tea extract on blood lipid and liver function enzymes of non-alcoholic fatty liver rats
TABLE 2 influence of Russian tea extract on blood lipid and liver function enzymes of non-alcoholic fatty liver rats
Note: superscript with significant differences compared to control#(p<0.05); the superscript of the significant difference compared to the model group is: (p)<0.05)。
As can be seen from Table 2, the serum levels of triglyceride and total cholesterol were significantly increased in the model group compared to the control group (p < 0.05). Compared with the model group, the Russian tea alcohol extract group (AL and AH) and the water extract group (WL and WH) can remarkably reduce the content of triglyceride and total cholesterol in serum, wherein the effect of high dosage of the alcohol extract is closest to that of the control group. In addition, compared with a control group, the ALT and AST content in the serum of the model group is obviously increased, which indicates that the lipid metabolism exceeds the bearing capacity of the liver under high-fat diet, thereby causing the liver injury; however, compared with the model group, the serum ALT and AST contents of the rats in each administration group are remarkably reduced, which indicates that the Russian tea extract can effectively prevent and treat liver injury caused by high fat, and particularly has the best effect of high-dose alcohol extract.
2.2.3 results of the Effect of Russian tea on the pathological conditions of liver tissues of NAFLD rats
Pathological section of rat liver As shown in FIG. 1, when a section of non-alcoholic fatty liver was observed under a light microscope, the shape of hepatocytes was normal, the state of nuclei was normal, and no fat particles were formed in the hepatocytes in the section of rats of the A control group.
In the B model group, the accumulation of nuclei and the damage of hepatocytes were clearly observed, and not only the formation of fat particles in hepatocytes was also clearly observed.
In the group with low concentration of C alcohol extract and the group with high concentration of D alcohol extract, the damage of lipid peroxidation to liver is greatly reduced, and the formation of fat particles is less.
The low-concentration group of the aqueous extract E and the high-concentration group of the aqueous extract F were slightly weaker than the alcohol extract in their ability to inhibit the damage of lipid peroxidation to hepatocytes, but were still better than the model group, and no significant fat particle formation was observed in the slices.
As can be seen from the slice image (fig. 2) of immunohistochemical FAS, the expression level of fatty acid synthase was very high in the B model group (yellow portion), but the content of fatty acid synthase in the administration group (C alcohol extract low concentration group, D alcohol extract high concentration group, E water extract low concentration group, and F water extract high concentration group) was significantly decreased, reducing fatty acid synthesis in the liver, and thus effectively inhibiting NAFLD formation.
It can be seen from the above examples that the russian tea can effectively inhibit the accumulation of fat in liver cells caused by long-term high-fat diet, and can effectively prevent the damage of the fat to the liver cells (the alcohol extract is more effective than the water extract). The Russian tea extract can be used for preventing and treating NAFLD and liver injury.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. Application of Russian tea and/or Russian tea extract in preparing medicine for preventing and treating non-alcoholic liver disease is provided.
2. The use of claim 1, wherein the non-alcoholic liver disease comprises non-alcoholic fatty liver disease and/or non-alcoholic fatty liver complications.
3. Application of Russian tea and/or Russian tea extract in preparing medicine for preventing and treating non-alcoholic liver injury is provided.
4. Application of Russian tea and/or Russian tea extract in preparing food, health product or medicine for protecting liver and/or inhibiting fat particle deposition in liver is provided.
5. The use according to any one of claims 1 to 4, wherein the medicament further comprises a pharmaceutically acceptable excipient.
6. The use of any one of claims 1 to 4, wherein the medicament is in the form of a powder, granule, pill, tablet, capsule, paste or decoction.
7. The use of any one of claims 1 to 4, wherein the Russian tea extract comprises Russian tea alcohol extract and/or Russian tea water extract.
8. The use of claim 7, wherein the Russian tea alcohol extract is prepared by the following method: mixing Russian tea with an ethanol water solution, performing ultrasonic extraction to obtain a crude extract, centrifuging the crude extract, and collecting the supernatant to obtain Russian tea ethanol extract; the volume percentage of the ethanol in the ethanol water solution is 75-85%.
9. The application of claim 8, wherein the temperature of ultrasonic extraction is 20-30 ℃, the time is 25-35 min, and the ultrasonic power is 30-40 Kw.
10. The use of claim 7, wherein the aqueous Russian tea extract is prepared by the following method: mixing the Russian tea with water, boiling for 0.8-1.5 h at 95-105 ℃ to obtain a crude extract, centrifuging the crude extract, and collecting the supernatant to obtain the Russian tea water extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911069426.1A CN110840950A (en) | 2019-11-05 | 2019-11-05 | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911069426.1A CN110840950A (en) | 2019-11-05 | 2019-11-05 | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110840950A true CN110840950A (en) | 2020-02-28 |
Family
ID=69599350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911069426.1A Withdrawn CN110840950A (en) | 2019-11-05 | 2019-11-05 | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110840950A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114432370A (en) * | 2020-11-02 | 2022-05-06 | 四川智佳成生物科技有限公司 | Russian fruit extract and pharmaceutical application thereof |
-
2019
- 2019-11-05 CN CN201911069426.1A patent/CN110840950A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114432370A (en) * | 2020-11-02 | 2022-05-06 | 四川智佳成生物科技有限公司 | Russian fruit extract and pharmaceutical application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106336445B (en) | The preparation method and application of compound 20 (R) ginseng sapoglycoside Rg 3 | |
| CN108042627B (en) | Composition for treating hyperuricemia and preparation method and application thereof | |
| Wu et al. | Hypoglycemic effect of okra aqueous extract on streptozotocin-induced diabetic rats | |
| CN105983016B (en) | A pharmaceutical composition containing silybin | |
| CN107551001B (en) | A Chinese medicinal composition for preventing and treating alcoholic hepatic injury and its preparation method | |
| CN110840950A (en) | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury | |
| CN103800352B (en) | Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof | |
| CN105920051B (en) | Flammulina velutipes extract and preparation method and application thereof | |
| CN102692477B (en) | Medicinal composition used for treating fatty liver and quality detection method thereof | |
| CN113730464A (en) | New application of rhizoma coptidis pill, extract and pharmaceutical composition thereof and rhizoma coptidis pill product | |
| CN115006494B (en) | Inula flower composite anti-alcohol composition with pulse-displaying function, anti-alcohol and liver-protecting preparation and application thereof | |
| KR101537856B1 (en) | A pharmaceutical composition for preventing and treating nonalcoholic fatty liver disease comprising extraction fraction with enhanced gincenoside rb1 from panax ginseng as an active ingredient | |
| CN104189294B (en) | A kind of compound Chinese medicinal preparation for treating non-alcoholic fatty liver disease and preparation method thereof | |
| CN103610048B (en) | To chemical damage health food having assistant protection function and preparation method thereof | |
| CN113350453B (en) | Composition for raising HDL-C | |
| KR101952648B1 (en) | The Inhibitory Effects of Amomum vilosum Loureiro Extracts and Composition Containing the Extract as Effective Ingredient | |
| CN110693873B (en) | Preparation and application of rabdosia rubescens active ingredient composition | |
| CN106074662B (en) | A kind of turmeric composition with effects of relieving alcoholism and protecting liver | |
| CN106535912A (en) | Pharmaceutical composition for controlling blood lipids and body weight, and use thereof | |
| CN106822095A (en) | A kind of medicine and its application in pharmacy for preventing and treating fatty liver and obesity | |
| CN106995479A (en) | Compound ginsenoside Rk1 preparation method and application | |
| CN110882319A (en) | Application of thoroughfare bitter orange, thoroughfare bitter orange extract and products containing thoroughfare bitter orange extract in preventing and/or treating metabolic liver diseases | |
| CN109966283A (en) | Application of the degreasing cinnamon polyphenol extract in preparation prevention and treatment diabetic nephropathy product | |
| CN104688800B (en) | Application of the total saponins from Cornus officinalis in the drug of preparation prevention and treatment diabetic complication | |
| CN113694105B (en) | Composition with blood fat reducing function and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200228 |